Aktienanalyse zu Icecure Medical Ltd (ICCM)ICCMIcecure Medical Ltd

Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized. It operates in the Healthcare sector.

Icecure Medical Ltd is currently not a good buy due to significant financial losses and a very low current price of $2.30, despite some positive revenue growth. The company reported a 45% revenue growth in H1 2026, reaching $1.8 million, but also widened its net loss to $8.8 million. The RSI is at a low 21.67, indicating potential oversold conditions, but the overall financial health remains concerning with a forward P/E of 0 and a gross margin of only 27.89%.